WASHINGTON – The U.S. has sent to Brazil more than 2 million doses of a malaria drug touted by President Donald Trump as potentially protecting against and treating the coronavirus, even though scientific evidence has not backed up those uses.
No large, rigorous scientific studies have found the drug, hydroxychloroquine, safe or effective for preventing or treating COVID-19, and some smaller studies have indicated worse outcomes from those taking the drug.
Brazil, now Latin America’s hardest-hit country, continues to see a surge in virus cases, and last week Trump announced that the U.S. was restricting travel from the country to prevent travelers from spreading the virus in the U.S.
In a joint statement with the Brazilian government on Sunday, the White House said the doses of hydroxychloroquine had been sent to Brazil as a prophylactic for front-line health workers and as a therapeutic for those who may come down with the virus. The White House said it was also delivering 1,000 ventilators to Brazil.
Trump revealed in May that he took a two-week course of the drug to protect against the coronavirus, despite warnings from his own government that it should only be administered for COVID-19 in a hospital or research setting due to potentially fatal side effects.
Trump’s announcement that he was taking the drug was criticized by medical experts who warned his actions could encourage others to take the drug outside of a medical setting.
Trump said he decided to take hydroxychloroquine after two White House staffers tested positive for the disease.
Local journalism is essential.
Give directly to The Spokesman-Review's Northwest Passages community forums series -- which helps to offset the costs of several reporter and editor positions at the newspaper -- by using the easy options below. Gifts processed in this system are not tax deductible, but are predominately used to help meet the local financial requirements needed to receive national matching-grant funds.
Subscribe to the Coronavirus newsletter
Get the day’s latest Coronavirus news delivered to your inbox by subscribing to our newsletter.